98 related articles for article (PubMed ID: 25056130)
1. Cell-penetrating, dimeric α-helical peptides: nanomolar inhibitors of HIV-1 transcription.
Jang S; Hyun S; Kim S; Lee S; Lee IS; Baba M; Lee Y; Yu J
Angew Chem Int Ed Engl; 2014 Sep; 53(38):10086-9. PubMed ID: 25056130
[TBL] [Abstract][Full Text] [Related]
2. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
Nishikawa H; Nakamura S; Kodama E; Ito S; Kajiwara K; Izumi K; Sakagami Y; Oishi S; Ohkubo T; Kobayashi Y; Otaka A; Fujii N; Matsuoka M
Int J Biochem Cell Biol; 2009 Apr; 41(4):891-9. PubMed ID: 18834950
[TBL] [Abstract][Full Text] [Related]
3. Small HIV-1-Tat peptides inhibit HIV replication in cultured T-cells.
Löhr M; Kibler KV; Zachary I; Jeang KT; Selwood DL
Biochem Biophys Res Commun; 2003 Jan; 300(2):609-13. PubMed ID: 12504126
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain.
Zhang H; Curreli F; Zhang X; Bhattacharya S; Waheed AA; Cooper A; Cowburn D; Freed EO; Debnath AK
Retrovirology; 2011 May; 8():28. PubMed ID: 21539734
[TBL] [Abstract][Full Text] [Related]
5. Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production.
Kaushik N; Basu A; Palumbo P; Myers RL; Pandey VN
J Virol; 2002 Apr; 76(8):3881-91. PubMed ID: 11907228
[TBL] [Abstract][Full Text] [Related]
6. Potent inhibition of HIV-1 replication by backbone cyclic peptides bearing the Rev arginine rich motif.
Chaloin L; Smagulova F; Hariton-Gazal E; Briant L; Loyter A; Devaux C
J Biomed Sci; 2007 Sep; 14(5):565-84. PubMed ID: 17520355
[TBL] [Abstract][Full Text] [Related]
7. A novel peptide shows excellent anti-HIV-1 potency as a gp41 fusion inhibitor.
Liu W; An X; Wang J; Zhang X; Tan J; Zhou Z; Zeng Y
Bioorg Med Chem Lett; 2018 Mar; 28(5):910-914. PubMed ID: 29433929
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV-1 in CEM cells by a potent TAR decoy.
Lee SW; Gallardo HF; Gaspar O; Smith C; Gilboa E
Gene Ther; 1995 Aug; 2(6):377-84. PubMed ID: 7584112
[TBL] [Abstract][Full Text] [Related]
9. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
[TBL] [Abstract][Full Text] [Related]
10. Recent status of HIV-1 gene expression inhibitors.
Baba M
Antiviral Res; 2006 Sep; 71(2-3):301-6. PubMed ID: 16488488
[TBL] [Abstract][Full Text] [Related]
11. Artificial nucleobase-amino acid conjugates: a new class of TAR RNA binding agents.
Joly JP; Mata G; Eldin P; Briant L; Fontaine-Vive F; Duca M; Benhida R
Chemistry; 2014 Feb; 20(7):2071-9. PubMed ID: 24431237
[TBL] [Abstract][Full Text] [Related]
12. A peptide nucleic acid-neamine conjugate that targets and cleaves HIV-1 TAR RNA inhibits viral replication.
Riguet E; Tripathi S; Chaubey B; Désiré J; Pandey VN; Décout JL
J Med Chem; 2004 Sep; 47(20):4806-9. PubMed ID: 15369382
[TBL] [Abstract][Full Text] [Related]
13. Amphiphilic helical peptides containing two acridine moieties display picomolar affinity toward HIV-1 RRE and TAR.
Lee Y; Hyun S; Kim HJ; Yu J
Angew Chem Int Ed Engl; 2008; 47(1):134-7. PubMed ID: 17987636
[No Abstract] [Full Text] [Related]
14. Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
Rawal RK; Tripathi R; Katti SB; Pannecouque C; De Clercq E
Eur J Med Chem; 2008 Dec; 43(12):2800-6. PubMed ID: 18242784
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat-TAR interaction inhibitors.
Chen S; Chen R; He M; Pang R; Tan Z; Yang M
Bioorg Med Chem; 2009 Mar; 17(5):1948-56. PubMed ID: 19217787
[TBL] [Abstract][Full Text] [Related]
16. A novel and efficient approach to discriminate between pre- and post-transcription HIV inhibitors.
Daelemans D; Pannecouque C; Pavlakis GN; Tabarrini O; De Clercq E
Mol Pharmacol; 2005 May; 67(5):1574-80. PubMed ID: 15728798
[TBL] [Abstract][Full Text] [Related]
17. A new potential approach to block HIV-1 replication via protein-protein interaction and strand-transfer inhibition.
Ferro S; De Luca L; Lo Surdo G; Morreale F; Christ F; Debyser Z; Gitto R; Chimirri A
Bioorg Med Chem; 2014 Apr; 22(7):2269-79. PubMed ID: 24618511
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships of anti-HIV-1 peptides with disulfide linkage between D- and L-cysteine at positions i and i+3, respectively, derived from HIV-1 gp41 C-peptide.
Lee MK; Kim HK; Lee TY; Hahm KS; Kim KL
Exp Mol Med; 2006 Feb; 38(1):18-26. PubMed ID: 16520549
[TBL] [Abstract][Full Text] [Related]
19. A cell-penetrating helical peptide as a potential HIV-1 inhibitor.
Zhang H; Zhao Q; Bhattacharya S; Waheed AA; Tong X; Hong A; Heck S; Curreli F; Goger M; Cowburn D; Freed EO; Debnath AK
J Mol Biol; 2008 May; 378(3):565-80. PubMed ID: 18374356
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of protein-RNA complexation that target the RNA: specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules.
Mei HY; Cui M; Heldsinger A; Lemrow SM; Loo JA; Sannes-Lowery KA; Sharmeen L; Czarnik AW
Biochemistry; 1998 Oct; 37(40):14204-12. PubMed ID: 9760258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
